A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal–Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes

被引：0
|
作者：
Sultan Linjawi
Byung-Wan Lee
Ömür Tabak
Susanna Lövdahl
Shanti Werther
Salahedeen Abusnana
机构：
[1] Coffs Endocrine and Diabetes Service,Division of Endocrinology and Metabolism, Department of Internal Medicine
[2] Yonsei University College of Medicine,Internal Medicine Clinic
[3] Ministry of Health Istanbul Kanuni Sultan Suleyman Training and Research Hospital,undefined
[4] Novo Nordisk A/S,undefined
[5] Rashid Center for Diabetes and Research,undefined
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Basal–bolus; BIAsp 30; Stepwise insulin intensification; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 11
页数：10
相关论文
共 50 条
  • [21] Efficacy of Insulin Degludec/Insulin Aspart (IDegAsp) vs. Insulin Glargine (IGlarU300) in Insulin-Naïve Patients with Type 2 Diabetes: A Retrospective Study
    Hasnani, Dhruvi
    Jha, Santosh
    Saboo, Banshi
    Prasanna, Pusala Lakshmi
    Sanghvi, Ami
    Sowani, Alpana
    Chavda, Vipul
    CLINICAL DIABETOLOGY, 2024, 13 (01): : 67 - 75
  • [22] Comparison of insulin aspart, regular insulin, and insulin lispro in basal bolus therapy with NPH to treat pediatric patients with type 1 diabetes mellitus
    Arslanian, S
    Foster, C
    Wright, N
    Stender, S
    Hu, P
    Hale, P
    Hale, D
    DIABETES, 2005, 54 : A517 - A518
  • [23] Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: The PRIEFER study
    Liebl, Andreas
    Prager, Rudolf
    Kaiser, Marcel
    Binz, Katharina
    Gallwitz, Baptist
    DIABETES, 2006, 55 : A123 - A123
  • [24] Initiating insulin therapy in type 2 diabetes - A comparison of biphasic and basal insulin analogs
    Raskin, P
    Hu, P
    Allen, E
    Bode, B
    Hollander, P
    Garber, A
    Lewin, A
    Gabbay, RA
    DIABETES CARE, 2005, 28 (02) : 260 - 265
  • [25] Type 1 diabetes patients can temporarily switch from continuous subcutaneous insulin infusion with insulin aspart to basal bolus therapy with insulin aspart and insulin glargine
    Bode, B
    Hirsch, I
    Hu, P
    Santiago, O
    DIABETES, 2003, 52 : A102 - A102
  • [26] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    DIABETOLOGIA, 2011, 54 : S423 - S423
  • [27] Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial
    Kaneko, Shizuka
    Chow, Francis
    Choi, Dong Seop
    Taneda, Shinji
    Hirao, Koichi
    Park, Yongsoo
    Andersen, Thomas Hasseriis
    Gall, Mari-Anne
    Christiansen, Jens Sandahl
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 107 (01) : 139 - 147
  • [28] Insulin Degludec/Insulin Aspart (IDegAsp) Provides Superior FPG Control and Reduced Hypoglycaemia vs. Biphasic Insulin Aspart 30 (BIAsp 30) in Insulin-Naive Adults with Type 2 Diabetes in a Randomized Phase 3 Trial
    Franek, Edward
    Haluzik, Martin
    Canecki-Varzic, Silvija
    Sargin, Mehmet
    Macura, Stanislava
    Zacho, Jeppe
    Christiansen, Jens Sandahl
    DIABETES, 2014, 63 : A225 - A225
  • [29] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN
    Saiyarsarai, P.
    Khosroshahi, Ghazizadeh A.
    Khedmati, J.
    Ghaffari, S.
    Soleymani, F.
    Seyyedifar, M.
    VALUE IN HEALTH, 2019, 22 : S576 - S576
  • [30] Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes
    K. Hermansen
    P. Fontaine
    K. K. Kukolja
    V. Peterkova
    G. Leth
    M.-A. Gall
    Diabetologia, 2004, 47 : 622 - 629
12345